Abstract:BRCA1/2 are breast cancer susceptibility genes that are involved in DNA repair and transcriptional control. They are dysregulated in breast cancer, making them attractive therapeutic targets. Here, we performed a systematic multiomics analysis to expound BRCA1/2 functions as prognostic biomarkers in breast cancer. First, using different web-based bioinformatics platforms (Oncomine, TIMER 2.0, UALCAN, and cBioportal), the expression of BRCA1/2 was assessed. Then, the R package was used to analyze the diagnostic value of BRCA1/2 in patients. Next, we determined the relationship between BRCA1/2 mRNA expression and prognosis in patients (PrognoScan Database, R2: Kaplan Meier Scanner and Kaplan–Meier Plotter). Subsequently, the association of BRCA1/2 with mutation frequency alteration and copy number alterations in breast cancer was investigated using the cBioportal platform. After that, we identified known and predicted structural genes and proteins essential for BRCA1/2 functions using GeneMania and STRING db. Finally, GO and KEGG pathway enrichment analyses were performed to elucidate the potential biological functions of the co-expression genes of BRCA1/2. The BRCA1/2 mRNA level in breast cancer tissues was considerably higher than in normal tissues, with AUCs of 0.766 and 0.829, respectively. Overexpression of BRCA1/2 was significantly related to the worse overall survival (p < 0.001) and was correlated to clinicopathological characteristics including lymph nodes, estrogen receptors, and progesterone receptors (p < 0.01). The alteration frequencies of both the gens have been checked, and the results show that BRCA1 and BRCA2 show different alteration frequencies. Their mutation sites differ from each other. GO and KEGG showed that BRCA1/2 was mainly enriched in catalytic activity, acting on DNA, chromosomal region, organelle fission, cell cycle, etc. The 20 most frequently changed genes were closely related to BRCA1/2, including PALB2 and RAD51 relatively. Our study provides suggestive evidence of the prognostic role of BRCA1/2 in breast cancer and the therapeutic target for breast cancer. Furthermore, BRCA1/2 may influence BRCA prognosis through catalytic activity, acting on DNA, chromosomal regions, organelle fission, and the cell cycle. Nevertheless, further validation is warranted.

BRCA1 regulates gene expression for orderly mitotic progression.

BRCA1 Regulates Human Mammary Stem/progenitor Cell Fate

Regulation of BRCA1 and BRCA2 Expression in Human Breast Cancer Cells by DNA-damaging Agents.

A Requirement for Breast-Cancer-Associated Gene 1 (brca1) in the Spindle Checkpoint

BRCA1 As a Potential Human Prostate Tumor Suppressor: Modulation of Proliferation, Damage Responses and Expression of Cell Regulatory Proteins

BRCA1 is required for meiotic spindle assembly and spindle assembly checkpoint activation in mouse oocytes.

Abstract #4440: BRCA1 Modulates Malignant Cell Behavior, the Expression of Survivin and Chemosensitivity in Human Breast Cancer Cells

BRCA1: Cell Cycle Checkpoint, Genetic Instability, DNA Damage Response and Cancer Evolution

Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1.

Brca2 Suppresses Cell Proliferation Via Stabilizing Mage-D1

Brca1 Gene In Breast Cancer

BRCA1 inhibition of telomerase activity in cultured cells.

Data from BRCA1 Induces Antioxidant Gene Expression and Resistance to Oxidative Stress

BRCA1 in hormone-responsive cancers.

BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma

Centrosome Amplification and A Defective G(2)-M Cell Cycle Checkpoint Induce Genetic Instability in Brca1 Exon 11 Isoform-Deficient Cells

Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity.

The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.

BRCA1 regulation of transcription

Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl

Roles of BRCA1 and Its Interacting Proteins.